#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Fetal Alcohol Spectrum Disorder ( FASD ) results from alcohol use during pregnancy creating lifelong functional and cognitive impairments that fall across a spectrum .
2-1	16-21	Fetal	abstract[4]	new[4]	appos	2-6[0_4]
2-2	22-29	Alcohol	substance|abstract[4]	new|new[4]	coref	2-10
2-3	30-38	Spectrum	person|abstract[4]	new|new[4]	coref	4-28[28_0]
2-4	39-47	Disorder	abstract[4]	new[4]	_	_
2-5	48-49	(	_	_	_	_
2-6	50-54	FASD	abstract	giv	coref	3-5
2-7	55-56	)	_	_	_	_
2-8	57-64	results	_	_	_	_
2-9	65-69	from	_	_	_	_
2-10	70-77	alcohol	substance|abstract[7]	giv|new[7]	coref|coref|coref|coref	6-21|6-21[39_7]|6-21|6-21[39_7]
2-11	78-81	use	abstract[7]	new[7]	_	_
2-12	82-88	during	_	_	_	_
2-13	89-98	pregnancy	event	new	coref	6-24
2-14	99-107	creating	_	_	_	_
2-15	108-116	lifelong	abstract[9]	new[9]	_	_
2-16	117-127	functional	abstract[9]	new[9]	_	_
2-17	128-131	and	abstract[9]	new[9]	_	_
2-18	132-141	cognitive	abstract[9]	new[9]	_	_
2-19	142-153	impairments	abstract[9]	new[9]	_	_
2-20	154-158	that	_	_	_	_
2-21	159-163	fall	_	_	_	_
2-22	164-170	across	_	_	_	_
2-23	171-172	a	abstract[10]	new[10]	_	_
2-24	173-181	spectrum	abstract[10]	new[10]	_	_
2-25	182-183	.	_	_	_	_

#Text=The actual prevalence of FASD is unknown , but recent estimates suggest a rate of 1.4 % – 4.4 % of the population in Alberta with 4 % identified as the best estimate in Canada .
3-1	184-187	The	abstract[11]	new[11]	coref	8-10[57_11]
3-2	188-194	actual	abstract[11]	new[11]	_	_
3-3	195-205	prevalence	abstract[11]	new[11]	_	_
3-4	206-208	of	abstract[11]	new[11]	_	_
3-5	209-213	FASD	abstract[11]|abstract	new[11]|giv	coref	4-15[23_0]
3-6	214-216	is	_	_	_	_
3-7	217-224	unknown	_	_	_	_
3-8	225-226	,	_	_	_	_
3-9	227-230	but	_	_	_	_
3-10	231-237	recent	abstract[13]	new[13]	_	_
3-11	238-247	estimates	abstract[13]	new[13]	_	_
3-12	248-255	suggest	_	_	_	_
3-13	256-257	a	abstract[14]	new[14]	_	_
3-14	258-262	rate	abstract[14]	new[14]	_	_
3-15	263-265	of	abstract[14]	new[14]	_	_
3-16	266-269	1.4	abstract[14]|quantity[15]	new[14]|new[15]	_	_
3-17	270-271	%	abstract[14]|quantity[15]	new[14]|new[15]	_	_
3-18	272-273	–	abstract[14]	new[14]	_	_
3-19	274-277	4.4	abstract[14]|quantity[16]	new[14]|new[16]	_	_
3-20	278-279	%	abstract[14]|quantity[16]	new[14]|new[16]	_	_
3-21	280-282	of	abstract[14]|quantity[16]	new[14]|new[16]	_	_
3-22	283-286	the	abstract[14]|quantity[16]|abstract[17]	new[14]|new[16]|new[17]	_	_
3-23	287-297	population	abstract[14]|quantity[16]|abstract[17]	new[14]|new[16]|new[17]	_	_
3-24	298-300	in	abstract[14]|quantity[16]|abstract[17]	new[14]|new[16]|new[17]	_	_
3-25	301-308	Alberta	abstract[14]|quantity[16]|abstract[17]|person	new[14]|new[16]|new[17]|new	coref	10-11[91_0]
3-26	309-313	with	_	_	_	_
3-27	314-315	4	quantity[19]	new[19]	_	_
3-28	316-317	%	quantity[19]	new[19]	_	_
3-29	318-328	identified	_	_	_	_
3-30	329-331	as	_	_	_	_
3-31	332-335	the	_	_	_	_
3-32	336-340	best	_	_	_	_
3-33	341-349	estimate	_	_	_	_
3-34	350-352	in	_	_	_	_
3-35	353-359	Canada	place	new	ana	4-1
3-36	360-361	.	_	_	_	_

#Text=It is thought that the vast majority of people affected are not diagnosed with the disorder either because their health problems are diagnosed under other categories or the individual does not come to the attention of diagnosticians .
4-1	362-364	It	place	giv	_	_
4-2	365-367	is	_	_	_	_
4-3	368-375	thought	_	_	_	_
4-4	376-380	that	_	_	_	_
4-5	381-384	the	person[22]	new[22]	ana	4-19[0_22]
4-6	385-389	vast	person[22]	new[22]	_	_
4-7	390-398	majority	person[22]	new[22]	_	_
4-8	399-401	of	person[22]	new[22]	_	_
4-9	402-408	people	person[22]	new[22]	_	_
4-10	409-417	affected	_	_	_	_
4-11	418-421	are	_	_	_	_
4-12	422-425	not	_	_	_	_
4-13	426-435	diagnosed	_	_	_	_
4-14	436-440	with	_	_	_	_
4-15	441-444	the	abstract[23]	giv[23]	coref	5-4[0_23]
4-16	445-453	disorder	abstract[23]	giv[23]	_	_
4-17	454-460	either	_	_	_	_
4-18	461-468	because	_	_	_	_
4-19	469-474	their	person|abstract[26]	giv|new[26]	_	_
4-20	475-481	health	abstract|abstract[26]	new|new[26]	coref	8-91
4-21	482-490	problems	abstract[26]	new[26]	_	_
4-22	491-494	are	_	_	_	_
4-23	495-504	diagnosed	_	_	_	_
4-24	505-510	under	_	_	_	_
4-25	511-516	other	abstract[27]	new[27]	_	_
4-26	517-527	categories	abstract[27]	new[27]	_	_
4-27	528-530	or	_	_	_	_
4-28	531-534	the	person[28]	giv[28]	_	_
4-29	535-545	individual	person[28]	giv[28]	_	_
4-30	546-550	does	_	_	_	_
4-31	551-554	not	_	_	_	_
4-32	555-559	come	_	_	_	_
4-33	560-562	to	_	_	_	_
4-34	563-566	the	abstract[29]	new[29]	_	_
4-35	567-576	attention	abstract[29]	new[29]	_	_
4-36	577-579	of	abstract[29]	new[29]	_	_
4-37	580-594	diagnosticians	abstract[29]|abstract	new[29]|new	_	_
4-38	595-596	.	_	_	_	_

#Text=In essence , FASD often goes unrecognized .
5-1	597-599	In	_	_	_	_
5-2	600-607	essence	_	_	_	_
5-3	608-609	,	_	_	_	_
5-4	610-614	FASD	abstract	giv	coref	7-10
5-5	615-620	often	_	_	_	_
5-6	621-625	goes	_	_	_	_
5-7	626-638	unrecognized	_	_	_	_
5-8	639-640	.	_	_	_	_

#Text=Prevention efforts have been ongoing for over two decades with a focus on broad messaging about the importance of avoiding alcohol use during pregnancy , but these efforts , while creating awareness , have not necessarily changed alcohol use behavior .
6-1	641-651	Prevention	abstract|event[33]	new|new[33]	coref|coref|coref|coref	6-27[41_33]|7-2|6-27[41_33]|7-2
6-2	652-659	efforts	event[33]	new[33]	_	_
6-3	660-664	have	_	_	_	_
6-4	665-669	been	_	_	_	_
6-5	670-677	ongoing	_	_	_	_
6-6	678-681	for	_	_	_	_
6-7	682-686	over	time[34]	new[34]	_	_
6-8	687-690	two	time[34]	new[34]	_	_
6-9	691-698	decades	time[34]	new[34]	_	_
6-10	699-703	with	time[34]	new[34]	_	_
6-11	704-705	a	time[34]|abstract[35]	new[34]|new[35]	_	_
6-12	706-711	focus	time[34]|abstract[35]	new[34]|new[35]	_	_
6-13	712-714	on	time[34]|abstract[35]	new[34]|new[35]	_	_
6-14	715-720	broad	time[34]|abstract[35]|abstract[36]	new[34]|new[35]|new[36]	coref	15-20[131_36]
6-15	721-730	messaging	time[34]|abstract[35]|abstract[36]	new[34]|new[35]|new[36]	_	_
6-16	731-736	about	time[34]|abstract[35]|abstract[36]	new[34]|new[35]|new[36]	_	_
6-17	737-740	the	time[34]|abstract[35]|abstract[36]|abstract[37]	new[34]|new[35]|new[36]|new[37]	_	_
6-18	741-751	importance	time[34]|abstract[35]|abstract[36]|abstract[37]	new[34]|new[35]|new[36]|new[37]	_	_
6-19	752-754	of	_	_	_	_
6-20	755-763	avoiding	_	_	_	_
6-21	764-771	alcohol	substance|abstract[39]	giv|giv[39]	coref|coref|coref|coref	6-38|6-39[0_39]|6-38|6-39[0_39]
6-22	772-775	use	abstract[39]	giv[39]	_	_
6-23	776-782	during	abstract[39]	giv[39]	_	_
6-24	783-792	pregnancy	abstract[39]|event	giv[39]|giv	coref	8-38
6-25	793-794	,	_	_	_	_
6-26	795-798	but	_	_	_	_
6-27	799-804	these	event[41]	giv[41]	coref	7-4[48_41]
6-28	805-812	efforts	event[41]	giv[41]	_	_
6-29	813-814	,	_	_	_	_
6-30	815-820	while	_	_	_	_
6-31	821-829	creating	_	_	_	_
6-32	830-839	awareness	abstract	new	coref	12-10[101_0]
6-33	840-841	,	_	_	_	_
6-34	842-846	have	_	_	_	_
6-35	847-850	not	_	_	_	_
6-36	851-862	necessarily	_	_	_	_
6-37	863-870	changed	_	_	_	_
6-38	871-878	alcohol	substance|abstract[45]	giv|new[45]	coref|coref	8-35|8-35
6-39	879-882	use	abstract|abstract[45]	giv|new[45]	_	_
6-40	883-891	behavior	abstract[45]	new[45]	_	_
6-41	892-893	.	_	_	_	_

#Text=Despite prevention and education efforts , the rates of FASD are thought to be much higher than previously considered , raising concerns that prevention has not been successful in reducing incidence .
7-1	894-901	Despite	_	_	_	_
7-2	902-912	prevention	abstract	giv	coref	7-24
7-3	913-916	and	_	_	_	_
7-4	917-926	education	person|event[48]	new|giv[48]	coref|coref	12-13|12-13
7-5	927-934	efforts	event[48]	giv[48]	_	_
7-6	935-936	,	_	_	_	_
7-7	937-940	the	abstract[49]	new[49]	_	_
7-8	941-946	rates	abstract[49]	new[49]	_	_
7-9	947-949	of	abstract[49]	new[49]	_	_
7-10	950-954	FASD	abstract[49]|abstract	new[49]|giv	coref	8-17[59_0]
7-11	955-958	are	_	_	_	_
7-12	959-966	thought	_	_	_	_
7-13	967-969	to	_	_	_	_
7-14	970-972	be	_	_	_	_
7-15	973-977	much	_	_	_	_
7-16	978-984	higher	_	_	_	_
7-17	985-989	than	_	_	_	_
7-18	990-1000	previously	_	_	_	_
7-19	1001-1011	considered	_	_	_	_
7-20	1012-1013	,	_	_	_	_
7-21	1014-1021	raising	_	_	_	_
7-22	1022-1030	concerns	abstract[51]	new[51]	_	_
7-23	1031-1035	that	abstract[51]	new[51]	_	_
7-24	1036-1046	prevention	abstract[51]|abstract	new[51]|giv	coref	12-16
7-25	1047-1050	has	abstract[51]	new[51]	_	_
7-26	1051-1054	not	abstract[51]	new[51]	_	_
7-27	1055-1059	been	abstract[51]	new[51]	_	_
7-28	1060-1070	successful	abstract[51]	new[51]	_	_
7-29	1071-1073	in	_	_	_	_
7-30	1074-1082	reducing	_	_	_	_
7-31	1083-1092	incidence	abstract	new	_	_
7-32	1093-1094	.	_	_	_	_

#Text=Hoyme , Kalberg , Elliot et al. indicate that the “ soaring prevalence and burden of FASD in children recently led the American Academy of Pediatrics to stress the following : no amount of alcohol intake during pregnancy can be considered safe ; there is no safe trimester to drink alcohol ; all forms of alcohol pose a similar risk ; and binge drinking poses a dose-related risk to the fetus ” ( p. 2 ) and , as noted above , many cases of FASD simply go unrecognized by health and helping professionals .
8-1	1095-1100	Hoyme	person	new	appos	8-3
8-2	1101-1102	,	_	_	_	_
8-3	1103-1110	Kalberg	person	giv	appos	8-5
8-4	1111-1112	,	_	_	_	_
8-5	1113-1119	Elliot	person	giv	_	_
8-6	1120-1122	et	_	_	_	_
8-7	1123-1126	al.	_	_	_	_
8-8	1127-1135	indicate	_	_	_	_
8-9	1136-1140	that	_	_	_	_
8-10	1141-1144	the	abstract[57]	giv[57]	coref	9-25[0_57]
8-11	1145-1146	“	abstract[57]	giv[57]	_	_
8-12	1147-1154	soaring	abstract[57]	giv[57]	_	_
8-13	1155-1165	prevalence	abstract[57]	giv[57]	_	_
8-14	1166-1169	and	_	_	_	_
8-15	1170-1176	burden	abstract[58]	new[58]	_	_
8-16	1177-1179	of	abstract[58]	new[58]	_	_
8-17	1180-1184	FASD	abstract[58]|abstract[59]	new[58]|giv[59]	coref	8-86[0_59]
8-18	1185-1187	in	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
8-19	1188-1196	children	abstract[58]|abstract[59]|person	new[58]|giv[59]|new	_	_
8-20	1197-1205	recently	_	_	_	_
8-21	1206-1209	led	_	_	_	_
8-22	1210-1213	the	organization[61]	new[61]	_	_
8-23	1214-1222	American	organization[61]	new[61]	_	_
8-24	1223-1230	Academy	organization[61]	new[61]	_	_
8-25	1231-1233	of	organization[61]	new[61]	_	_
8-26	1234-1244	Pediatrics	organization[61]	new[61]	_	_
8-27	1245-1247	to	_	_	_	_
8-28	1248-1254	stress	_	_	_	_
8-29	1255-1258	the	event[62]	new[62]	_	_
8-30	1259-1268	following	event[62]	new[62]	_	_
8-31	1269-1270	:	event[62]	new[62]	_	_
8-32	1271-1273	no	event[62]|abstract[63]	new[62]|new[63]	_	_
8-33	1274-1280	amount	event[62]|abstract[63]	new[62]|new[63]	_	_
8-34	1281-1283	of	event[62]|abstract[63]	new[62]|new[63]	_	_
8-35	1284-1291	alcohol	event[62]|abstract[63]|substance|event[65]	new[62]|new[63]|giv|new[65]	coref|coref	8-51|8-51
8-36	1292-1298	intake	event[62]|abstract[63]|event[65]	new[62]|new[63]|new[65]	_	_
8-37	1299-1305	during	event[62]|abstract[63]|event[65]	new[62]|new[63]|new[65]	_	_
8-38	1306-1315	pregnancy	event[62]|abstract[63]|event[65]|event	new[62]|new[63]|new[65]|giv	_	_
8-39	1316-1319	can	event[62]	new[62]	_	_
8-40	1320-1322	be	event[62]	new[62]	_	_
8-41	1323-1333	considered	event[62]	new[62]	_	_
8-42	1334-1338	safe	event[62]	new[62]	_	_
8-43	1339-1340	;	_	_	_	_
8-44	1341-1346	there	_	_	_	_
8-45	1347-1349	is	_	_	_	_
8-46	1350-1352	no	substance[67]	new[67]	_	_
8-47	1353-1357	safe	substance[67]	new[67]	_	_
8-48	1358-1367	trimester	substance[67]	new[67]	_	_
8-49	1368-1370	to	_	_	_	_
8-50	1371-1376	drink	_	_	_	_
8-51	1377-1384	alcohol	substance	giv	coref	8-56
8-52	1385-1386	;	_	_	_	_
8-53	1387-1390	all	substance[69]	new[69]	_	_
8-54	1391-1396	forms	substance[69]	new[69]	_	_
8-55	1397-1399	of	substance[69]	new[69]	_	_
8-56	1400-1407	alcohol	substance[69]|substance	new[69]|giv	_	_
8-57	1408-1412	pose	_	_	_	_
8-58	1413-1414	a	abstract[71]	new[71]	coref	8-66[73_71]
8-59	1415-1422	similar	abstract[71]	new[71]	_	_
8-60	1423-1427	risk	abstract[71]	new[71]	_	_
8-61	1428-1429	;	_	_	_	_
8-62	1430-1433	and	_	_	_	_
8-63	1434-1439	binge	event	new	_	_
8-64	1440-1448	drinking	_	_	_	_
8-65	1449-1454	poses	_	_	_	_
8-66	1455-1456	a	abstract[73]	giv[73]	_	_
8-67	1457-1469	dose-related	abstract[73]	giv[73]	_	_
8-68	1470-1474	risk	abstract[73]	giv[73]	_	_
8-69	1475-1477	to	abstract[73]	giv[73]	_	_
8-70	1478-1481	the	abstract[73]|object[74]	giv[73]|new[74]	_	_
8-71	1482-1487	fetus	abstract[73]|object[74]	giv[73]|new[74]	_	_
8-72	1488-1489	”	_	_	_	_
8-73	1490-1491	(	_	_	_	_
8-74	1492-1494	p.	abstract[75]	new[75]	_	_
8-75	1495-1496	2	abstract[75]	new[75]	_	_
8-76	1497-1498	)	_	_	_	_
8-77	1499-1502	and	_	_	_	_
8-78	1503-1504	,	_	_	_	_
8-79	1505-1507	as	_	_	_	_
8-80	1508-1513	noted	_	_	_	_
8-81	1514-1519	above	_	_	_	_
8-82	1520-1521	,	_	_	_	_
8-83	1522-1526	many	abstract[76]	new[76]	_	_
8-84	1527-1532	cases	abstract[76]	new[76]	_	_
8-85	1533-1535	of	abstract[76]	new[76]	_	_
8-86	1536-1540	FASD	abstract[76]|abstract	new[76]|giv	coref	10-1
8-87	1541-1547	simply	_	_	_	_
8-88	1548-1550	go	_	_	_	_
8-89	1551-1563	unrecognized	_	_	_	_
8-90	1564-1566	by	_	_	_	_
8-91	1567-1573	health	abstract	giv	_	_
8-92	1574-1577	and	_	_	_	_
8-93	1578-1585	helping	_	_	_	_
8-94	1586-1599	professionals	person	new	_	_
8-95	1600-1601	.	_	_	_	_

#Text=We are cautious with this data , as , given that screening and diagnostic criteria and methods are changing , this may confound the prevalence data .
9-1	1602-1604	We	person	acc	_	_
9-2	1605-1608	are	_	_	_	_
9-3	1609-1617	cautious	_	_	_	_
9-4	1618-1622	with	_	_	_	_
9-5	1623-1627	this	abstract[81]	new[81]	coref	9-24[87_81]
9-6	1628-1632	data	abstract[81]	new[81]	_	_
9-7	1633-1634	,	_	_	_	_
9-8	1635-1637	as	_	_	_	_
9-9	1638-1639	,	_	_	_	_
9-10	1640-1645	given	_	_	_	_
9-11	1646-1650	that	_	_	_	_
9-12	1651-1660	screening	abstract	new	ana	9-21
9-13	1661-1664	and	_	_	_	_
9-14	1665-1675	diagnostic	abstract[83]	new[83]	_	_
9-15	1676-1684	criteria	abstract[83]	new[83]	_	_
9-16	1685-1688	and	_	_	_	_
9-17	1689-1696	methods	abstract	new	_	_
9-18	1697-1700	are	_	_	_	_
9-19	1701-1709	changing	_	_	_	_
9-20	1710-1711	,	_	_	_	_
9-21	1712-1716	this	abstract	giv	_	_
9-22	1717-1720	may	_	_	_	_
9-23	1721-1729	confound	_	_	_	_
9-24	1730-1733	the	abstract[87]	giv[87]	coref	14-5[0_87]
9-25	1734-1744	prevalence	abstract|abstract[87]	giv|giv[87]	_	_
9-26	1745-1749	data	abstract[87]	giv[87]	_	_
9-27	1750-1751	.	_	_	_	_

#Text=FASD is a clearly established priority for the province of Alberta , Canada , which is where the research reported here was conducted .
10-1	1752-1756	FASD	abstract	giv	coref	10-3[89_0]
10-2	1757-1759	is	_	_	_	_
10-3	1760-1761	a	abstract[89]	giv[89]	coref	11-10[0_89]
10-4	1762-1769	clearly	abstract[89]	giv[89]	_	_
10-5	1770-1781	established	abstract[89]	giv[89]	_	_
10-6	1782-1790	priority	abstract[89]	giv[89]	_	_
10-7	1791-1794	for	abstract[89]	giv[89]	_	_
10-8	1795-1798	the	abstract[89]|place[90]	giv[89]|new[90]	_	_
10-9	1799-1807	province	abstract[89]|place[90]	giv[89]|new[90]	_	_
10-10	1808-1810	of	abstract[89]|place[90]	giv[89]|new[90]	_	_
10-11	1811-1818	Alberta	abstract[89]|place[90]|person[91]	giv[89]|new[90]|giv[91]	coref	11-7[0_91]
10-12	1819-1820	,	abstract[89]|place[90]|person[91]	giv[89]|new[90]|giv[91]	_	_
10-13	1821-1827	Canada	abstract[89]|place[90]|person[91]	giv[89]|new[90]|giv[91]	_	_
10-14	1828-1829	,	_	_	_	_
10-15	1830-1835	which	_	_	_	_
10-16	1836-1838	is	_	_	_	_
10-17	1839-1844	where	_	_	_	_
10-18	1845-1848	the	abstract[92]	new[92]	coref	13-1[114_92]
10-19	1849-1857	research	abstract[92]	new[92]	_	_
10-20	1858-1866	reported	_	_	_	_
10-21	1867-1871	here	_	_	_	_
10-22	1872-1875	was	_	_	_	_
10-23	1876-1885	conducted	_	_	_	_
10-24	1886-1887	.	_	_	_	_

#Text=In 2008 , the Government of Alberta implemented an FASD 10-Year Strategic Plan .
11-1	1888-1890	In	_	_	_	_
11-2	1891-1895	2008	time	new	_	_
11-3	1896-1897	,	_	_	_	_
11-4	1898-1901	the	organization[94]	new[94]	_	_
11-5	1902-1912	Government	organization[94]	new[94]	_	_
11-6	1913-1915	of	organization[94]	new[94]	_	_
11-7	1916-1923	Alberta	organization[94]|place	new[94]|giv	coref	14-24
11-8	1924-1935	implemented	_	_	_	_
11-9	1936-1938	an	abstract[98]	new[98]	coref	12-6[100_98]
11-10	1939-1943	FASD	organization|abstract[98]	giv|new[98]	coref	12-37
11-11	1944-1951	10-Year	abstract[98]	new[98]	_	_
11-12	1952-1961	Strategic	abstract|abstract[98]	new|new[98]	_	_
11-13	1962-1966	Plan	abstract[98]	new[98]	_	_
11-14	1967-1968	.	_	_	_	_

#Text=The first two pillars of that plan focus upon public awareness and education strategies and prevention , while the other pillars look at assessment and diagnosis , support for caregivers , and the presence of an FASD learning organization .
12-1	1969-1972	The	abstract[99]	new[99]	coref	12-19[105_99]
12-2	1973-1978	first	abstract[99]	new[99]	_	_
12-3	1979-1982	two	abstract[99]	new[99]	_	_
12-4	1983-1990	pillars	abstract[99]	new[99]	_	_
12-5	1991-1993	of	abstract[99]	new[99]	_	_
12-6	1994-1998	that	abstract[99]|abstract[100]	new[99]|giv[100]	_	_
12-7	1999-2003	plan	abstract[99]|abstract[100]	new[99]|giv[100]	_	_
12-8	2004-2009	focus	_	_	_	_
12-9	2010-2014	upon	_	_	_	_
12-10	2015-2021	public	abstract[101]	giv[101]	coref	13-5[115_101]
12-11	2022-2031	awareness	abstract[101]	giv[101]	_	_
12-12	2032-2035	and	_	_	_	_
12-13	2036-2045	education	person|abstract[103]	giv|new[103]	_	_
12-14	2046-2056	strategies	abstract[103]	new[103]	_	_
12-15	2057-2060	and	_	_	_	_
12-16	2061-2071	prevention	abstract	giv	_	_
12-17	2072-2073	,	_	_	_	_
12-18	2074-2079	while	_	_	_	_
12-19	2080-2083	the	abstract[105]	giv[105]	_	_
12-20	2084-2089	other	abstract[105]	giv[105]	_	_
12-21	2090-2097	pillars	abstract[105]	giv[105]	_	_
12-22	2098-2102	look	_	_	_	_
12-23	2103-2105	at	_	_	_	_
12-24	2106-2116	assessment	event	new	_	_
12-25	2117-2120	and	_	_	_	_
12-26	2121-2130	diagnosis	event	new	_	_
12-27	2131-2132	,	_	_	_	_
12-28	2133-2140	support	abstract[108]	new[108]	_	_
12-29	2141-2144	for	abstract[108]	new[108]	_	_
12-30	2145-2155	caregivers	abstract[108]|person	new[108]|new	_	_
12-31	2156-2157	,	_	_	_	_
12-32	2158-2161	and	_	_	_	_
12-33	2162-2165	the	abstract[110]	new[110]	_	_
12-34	2166-2174	presence	abstract[110]	new[110]	_	_
12-35	2175-2177	of	abstract[110]	new[110]	_	_
12-36	2178-2180	an	abstract[110]|organization[113]	new[110]|new[113]	ana	14-1[0_113]
12-37	2181-2185	FASD	abstract[110]|abstract|organization[113]	new[110]|giv|new[113]	coref	14-22[124_0]
12-38	2186-2194	learning	abstract[110]|abstract|organization[113]	new[110]|new|new[113]	_	_
12-39	2195-2207	organization	abstract[110]|organization[113]	new[110]|new[113]	_	_
12-40	2208-2209	.	_	_	_	_

#Text=This research looks at public awareness , which is part of the first pillar .
13-1	2210-2214	This	abstract[114]	giv[114]	_	_
13-2	2215-2223	research	abstract[114]	giv[114]	_	_
13-3	2224-2229	looks	_	_	_	_
13-4	2230-2232	at	_	_	_	_
13-5	2233-2239	public	abstract[115]	giv[115]	coref	14-19[123_115]
13-6	2240-2249	awareness	abstract[115]	giv[115]	_	_
13-7	2250-2251	,	_	_	_	_
13-8	2252-2257	which	_	_	_	_
13-9	2258-2260	is	_	_	_	_
13-10	2261-2265	part	_	_	_	_
13-11	2266-2268	of	_	_	_	_
13-12	2269-2272	the	abstract[116]	new[116]	_	_
13-13	2273-2278	first	abstract[116]	new[116]	_	_
13-14	2279-2285	pillar	abstract[116]	new[116]	_	_
13-15	2286-2287	.	_	_	_	_

#Text=It uses a secondary data analysis of the 2011 and 2017 datasets to examine characteristics and changes in public awareness of FASD in Alberta .
14-1	2288-2290	It	organization	giv	_	_
14-2	2291-2295	uses	_	_	_	_
14-3	2296-2297	a	abstract[119]	new[119]	_	_
14-4	2298-2307	secondary	abstract[119]	new[119]	_	_
14-5	2308-2312	data	abstract|abstract[119]	giv|new[119]	_	_
14-6	2313-2321	analysis	abstract[119]	new[119]	_	_
14-7	2322-2324	of	abstract[119]	new[119]	_	_
14-8	2325-2328	the	abstract[119]|object[120]	new[119]|new[120]	_	_
14-9	2329-2333	2011	abstract[119]|object[120]	new[119]|new[120]	_	_
14-10	2334-2337	and	abstract[119]|object[120]	new[119]|new[120]	_	_
14-11	2338-2342	2017	abstract[119]|object[120]	new[119]|new[120]	_	_
14-12	2343-2351	datasets	abstract[119]|object[120]	new[119]|new[120]	_	_
14-13	2352-2354	to	_	_	_	_
14-14	2355-2362	examine	_	_	_	_
14-15	2363-2378	characteristics	abstract	new	_	_
14-16	2379-2382	and	_	_	_	_
14-17	2383-2390	changes	abstract	new	_	_
14-18	2391-2393	in	_	_	_	_
14-19	2394-2400	public	abstract[123]	giv[123]	_	_
14-20	2401-2410	awareness	abstract[123]	giv[123]	_	_
14-21	2411-2413	of	abstract[123]	giv[123]	_	_
14-22	2414-2418	FASD	abstract[123]|abstract[124]	giv[123]|giv[124]	coref	15-12[0_124]
14-23	2419-2421	in	abstract[123]|abstract[124]	giv[123]|giv[124]	_	_
14-24	2422-2429	Alberta	abstract[123]|abstract[124]|place	giv[123]|giv[124]|giv	_	_
14-25	2430-2431	.	_	_	_	_

#Text=The present project looks to understand the degree of awareness of FASD , which can assist in understanding whether the messaging is at least impacting at that level .
15-1	2432-2435	The	abstract[126]	new[126]	_	_
15-2	2436-2443	present	abstract[126]	new[126]	_	_
15-3	2444-2451	project	abstract[126]	new[126]	_	_
15-4	2452-2457	looks	_	_	_	_
15-5	2458-2460	to	_	_	_	_
15-6	2461-2471	understand	_	_	_	_
15-7	2472-2475	the	abstract[127]	new[127]	_	_
15-8	2476-2482	degree	abstract[127]	new[127]	_	_
15-9	2483-2485	of	abstract[127]	new[127]	_	_
15-10	2486-2495	awareness	abstract[127]|abstract[128]	new[127]|new[128]	_	_
15-11	2496-2498	of	abstract[127]|abstract[128]	new[127]|new[128]	_	_
15-12	2499-2503	FASD	abstract[127]|abstract[128]|abstract	new[127]|new[128]|giv	_	_
15-13	2504-2505	,	_	_	_	_
15-14	2506-2511	which	_	_	_	_
15-15	2512-2515	can	_	_	_	_
15-16	2516-2522	assist	_	_	_	_
15-17	2523-2525	in	_	_	_	_
15-18	2526-2539	understanding	abstract	new	_	_
15-19	2540-2547	whether	_	_	_	_
15-20	2548-2551	the	abstract[131]	giv[131]	_	_
15-21	2552-2561	messaging	abstract[131]	giv[131]	_	_
15-22	2562-2564	is	_	_	_	_
15-23	2565-2567	at	_	_	_	_
15-24	2568-2573	least	_	_	_	_
15-25	2574-2583	impacting	_	_	_	_
15-26	2584-2586	at	_	_	_	_
15-27	2587-2591	that	abstract[132]	new[132]	_	_
15-28	2592-2597	level	abstract[132]	new[132]	_	_
15-29	2598-2599	.	_	_	_	_
